Piperlongumine inhibits NF-κB activity and attenuates aggressive growth characteristics of prostate cancer cells

Prostate

Volumn 74, Issue 2, 2014, Pages 177-186

  Ginzburg, Serge ^a   Golovine, Konstantin V ^a   Makhov, Petr B ^a   Uzzo, Robert G ^a   Kutikov, Alexander ^a   Kolenko, Vladimir M ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

adhesion; apoptosis; cytokines; IL 6; IL 8; MMP 9; NF B; piperlongumine; prostate cancer; ROS

Indexed keywords

ANTINEOPLASTIC ALKALOID; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; PIPERLONGUMINE; PROTEIN P50; SYNAPTOTAGMIN I; UNCLASSIFIED DRUG;

ARTICLE; CELL ADHESION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; WESTERN BLOTTING;

ADHESION; APOPTOSIS; CYTOKINES; IL-6; IL-8; MMP-9; NF-ΚB; PIPERLONGUMINE; PROSTATE CANCER; ROS;

ADENOCARCINOMA; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DIOXOLANES; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MATRIX METALLOPROTEINASE 9; NF-KAPPA B; PLANT EXTRACTS; PROSTATIC NEOPLASMS;

EID: 84891163325     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22739     Document Type: Article

References (56)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin 2013; 63 (1): 11-30.
2. El-Amm J, Aragon-Ching JB,. The changing landscape in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Med Oncol 2013; 5 (1): 25-40.
3. Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL Jr, Baker LH,. Vitamin E and the risk of prostate cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306 (14): 1549-1556.
4. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr., The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349 (3): 215-224.
5. Andriole GL, Bostwick D, Brawley OW, Gomella L, Marberger M, Montorsi F, Pettaway C, Tammela TL, Teloken C, Tindall D, Freedland SJ, Somerville MC, Wilson TH, Fowler I, Castro R, Rittmaster RS, Group RS,. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: Results from the REDUCE study. J Urol 2011; 185 (1): 126-131.
6. Walsh PC,. Chemoprevention of prostate cancer. N Engl J Med 2010; 362 (13): 1237-1238.
7. Theoret MR, Ning YM, Zhang JJ, Justice R, Keegan P, Pazdur R,. The risks and benefits of 5alpha-reductase inhibitors for prostate-cancer prevention. N Engl J Med 2011; 365 (2): 97-99.
8. Bernard CB, Krishnamurty HG, Chauret D, Durst T, Philogene BJR, Sanchezvindas P, Hasbun C, Poveda L, Sanroman L, Arnason JT,. Insecticidal defenses of piperaceae from the neotropics. J Chem Ecol 1995; 21 (6): 801-814.
9. Reddy PS, Jamil K, Madhusudhan P, Anjani G, Das B,. Antibacterial activity of isolates from Piper longum and Taxus baccata. Pharm Biol 2001; 39 (3): 236-238.
10. Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li X, Tolliday NJ, Golub TR, Carr SA, Shamji AF, Stern AM, Mandinova A, Schreiber SL, Lee SW,. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 2011; 475 (7355): 231-234.
11. Bezerra DP, Pessoa C, de Moraes MO, de Alencar NMN, Mesquita RO, Lima MW, Alves APNN, Pessoa ODL, Chaves JH, Silveira ER, Costa-Lotufo LV,. In vivo growth inhibition of sarcoma 180 by piperlonguminine, an alkaloid amide from the Piper species. J Appl Toxicol 2008; 28 (5): 599-607.
12. Golovine KV, Makhov PB, Teper E, Kutikov A, Canter D, Uzzo RG, Kolenko VM,. Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells. Prostate 2013; 73 (1): 23-30.
13. Kong EH, Kim YJ, Kim YJ, Cho HJ, Yu SN, Kim KY, Chang JH, Ahn SC,. Piplartine induces caspase-mediated apoptosis in PC-3 human prostate cancer cells. Oncol Rep 2008; 20 (4): 785-792.
14. Son DJ, Kim SY, Han SS, Kim CW, Kumar S, Park BS, Lee SE, Yun YP, Jo H, Park YH,. Piperlongumine inhibits atherosclerotic plaque formation and vascular smooth muscle cell proliferation by suppressing PDGF receptor signaling. Biochem Biophys Res Commun 2012; 427 (2): 349-354.
15. Suh J, Rabson AB,. NF-kappaB activation in human prostate cancer: Important mediator or epiphenomenon ? J Cell Biochem 2004; 91 (1): 100-117.
16. Suh J, Payvandi F, Edelstein LC, Amenta PS, Zong WX, Gelinas C, Rabson AB,. Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate 2002; 52 (3): 183-200.
17. Sweeney C, Li L, Shanmugam R, Bhat-Nakshatri P, Jayaprakasan V, Baldridge LA, Gardner T, Smith M, Nakshatri H, Cheng L,. Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res 2004; 10 (16): 5501-5507.
18. Eferl R, Wagner EF,. AP-1: A double-edged sword in tumorigenesis. Nat Rev Cancer 2003; 3 (11): 859-868.
19. Shukla S, Maclennan GT, Marengo SR, Resnick MI, Gupta S,. Constitutive activation of P I3 K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model. Prostate 2005; 64 (3): 224-239.
20. Gilmore TD,. The Rel/NF-kappaB signal transduction pathway: Introduction. Oncogene 1999; 18 (49): 6842-6844.
21. Pahl HL,. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999; 18 (49): 6853-6866.
22. Zerbini LF, Wang Y, Cho JY, Libermann TA,. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Res 2003; 63 (9): 2206-2215.
23. Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP,. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 1999; 17: 331-367.
24. Hsu H, Xiong J, Goeddel DV,. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 1995; 81 (4): 495-504.
25. Malinin NL, Boldin MP, Kovalenko AV, Wallach D,. MAP3K-related kinase involved in NF-kappaB induction by TNF CD95 and IL-1. Nature 1997; 385 (6616): 540-544.
26. Regnier CH, Song HY, Gao X, Goeddel DV, Cao Z, Rothe M,. Identification and characterization of an IkappaB kinase. Cell 1997; 90 (2): 373-383.
27. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M,. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature 1997; 388 (6642): 548-554.
28. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB,. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999; 401 (6748): 82-85.
29. Okamoto M, Lee C, Oyasu R,. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 1997; 57 (1): 141-146.
30. Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, Sonoda T, Hirano T, Kishimoto T,. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 1989; 250 (2): 607-610.
31. Li A, Varney ML, Singh RK,. Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials. Clin Cancer Res 2001; 7 (10): 3298-3304.
32. Ondrey FG, Dong G, Sunwoo J, Chen Z, Wolf JS, Crowl-Bancroft CV, Mukaida N, Van Waes C,. Constitutive activation of transcription factors NF-(kappa)B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. Mol Carcinog 1999; 26 (2): 119-129.
33. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ,. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001; 20 (31): 4188-4197.
34. Huang Q, Shen HM, Ong CN,. Inhibitory effect of emodin on tumor invasion through suppression of activator protein-1 and nuclear factor-kappaB. Biochem Pharmacol 2004; 68 (2): 361-371.
35. Bancroft CC, Chen Z, Yeh J, Sunwoo JB, Yeh NT, Jackson S, Jackson C, Van Waes C,. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 2002; 99 (4): 538-548.
36. Hao W, Zhu Y, Zhou H,. Prognostic value of interleukin-6 and interleukin-8 in laryngeal squamous cell cancer. Med Oncol 2013; 30 (1): 333.
37. Nakashima J, Tachibana M, Ueno M, Miyajima A, Baba S, Murai M,. Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clin Cancer Res 1998; 4 (7): 1743-1748.
38. Kolenko V, Bloom T, Rayman P, Bukowski R, Hsi E, Finke J,. Inhibition of NF-kappa B activity in human T lymphocytes induces caspase-dependent apoptosis without detectable activation of caspase-1 and -3. J Immunol 1999; 163 (2): 590-598.
39. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, Trapman J,. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 1998; 58 (13): 2720-2723.
40. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL,. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci USA 1998; 95 (26): 15587-15591.
41. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR,. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999; 59 (17): 4291-4296.
42. Mayo MW, Madrid LV, Westerheide SD, Jones DR, Yuan XJ, Baldwin AS Jr, Whang YE,. PTEN blocks tumor necrosis factor-induced NF-kappa B-dependent transcription by inhibiting the transactivation potential of the p65 subunit. J Biol Chem 2002; 277 (13): 11116-11125.
43. Gustin JA, Maehama T, Dixon JE, Donner DB,. The PTEN tumor suppressor protein inhibits tumor necrosis factor-induced nuclear factor kappa B activity. J Biol Chem 2001; 276 (29): 27740-27744.
44. McCall P, Bennett L, Ahmad I, MacKenzie LM, Forbes IWG, Leung HY, Sansom OJ, Orange C, Seywright M, Underwood MA, Edwards J,. NF kappa B signalling is upregulated in a subset of castrate-resistant prostate cancer patients and correlates with disease progression. Br J Cancer 2012; 107 (9): 1554-1563.
45. Dan HC, Cooper MJ, Cogswell PC, Duncan JA, Ting JP, Baldwin AS,. Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes Dev 2008; 22 (11): 1490-1500.
46. Uzzo RG, Crispen PL, Golovine K, Makhov P, Horwitz EM, Kolenko VM,. Diverse effects of zinc on NF-kappaB and AP-1 transcription factors: Implications for prostate cancer progression. Carcinogenesis 2006; 27 (10): 1980-1990.
47. Chung TD, Yu JJ, Spiotto MT, Bartkowski M, Simons JW,. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 1999; 38 (3): 199-207.
48. Aalinkeel R, Nair MP, Sufrin G, Mahajan SD, Chadha KC, Chawda RP, Schwartz SA,. Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells. Cancer Res 2004; 64 (15): 5311-5321.
49. Steeg PS,. Tumor metastasis: Mechanistic insights and clinical challenges. Nat Med 2006; 12 (8): 895-904.
50. Farina AR, Cappabianca L, Mackay AR, Tiberio A, Tacconelli A, Tessitore A, Frati L, Martinotti S, Gulino A,. Transcriptional regulation of intercellular adhesion molecule 1 by phorbol ester in human neuroblastoma cell line SK-N-SH involves jun- and fos-containing activator protein 1 site binding complex(es). Cell Growth Differ 1997; 8 (7): 789-800.
51. Crispen PL, Uzzo RG, Golovine K, Makhov P, Pollack A, Horwitz EM, Greenberg RE, Kolenko VM,. Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: Implications for chemoprevention. Prostate 2007; 67 (6): 582-590.
52. Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M,. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002; 62 (21): 6141-6145.
53. McCall P, Gemmell LK, Mukherjee R, Bartlett JM, Edwards J,. Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients. Br J Cancer 2008; 98 (6): 1094-1101.
54. Meng F, Liu L, Chin PC, D'Mello SR,. Akt is a downstream target of NF-kappa B. J Biol Chem 2002; 277 (33): 29674-29680.
55. Bezerra DP, Castro FO, Alves AP, Pessoa C, Moraes MO, Silveira ER, Lima MA, Elmiro FJ, Costa-Lotufo LV,. In vivo growth-inhibition of Sarcoma 180 by piplartine and piperine, two alkaloid amides from Piper. Braz J Med Biol Res 2006; 39 (6): 801-807.
56. Bezerra DP, de Castro FO, Alves AP, Pessoa C, de Moraes MO, Silveira ER, Lima MA, Elmiro FJ, de Alencar NM, Mesquita RO, Lima MW, Costa-Lotufo LV,. In vitro and in vivo antitumor effect of 5-FU combined with piplartine and piperine. J Appl Toxicol 2008; 28 (2): 156-163.